Latest Breaking News On - Targeted alpha - Page 1 : vimarsana.com

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

SYDNEY (BUSINESS WIRE) #CMO AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of

United statesSan franciscoStanford universityAnna karmannAndrew adamovichMckinsey companyTsinghua universityBristol myers squibbMaastricht universityUniversity medical center maastrichtStanford university hospitalAachen universityTargeted alpha therapiesChief medical officerInvestigational new drugAlpha therapies

Orano Med Announces Appointment of Dr Volker Wagner as Chief Medical Officer

Orano Med Announces Appointment of Dr Volker Wagner as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulien dodetClinical developmentHead of clinical development radiopharmaceuticals at bayerTargeted alpha therapiesVolker wagnerChief medicalVice presidentClinical development radiopharmaceuticalsTargeted alphaMedical affairsInternal medicineMedical oncologyOrano med

Orano Med Announces Appointment of Dr Volker Wagner as Chief Medical Officer

PARIS (BUSINESS WIRE) Regulatory News:Orano Med (Orano group subsidiary), a leading innovator in the field of Targeted Alpha Therapies in oncology, is thrilled to announce the appointment of Dr. Volker Wagner MD PhD as its new Chief Medical Officer. Dr. Wagner brings a wealth of experience and expertise to the rol.

United statesJulien dodetHead of clinical development radiopharmaceuticals at bayerClinical developmentRegulatory newsTargeted alpha therapiesVolker wagnerChief medicalVice presidentClinical development radiopharmaceuticalsTargeted alphaMedical affairsInternal medicineMedical oncologyOrano med

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

United statesLily ramseyUniklinik essenAndrew adamovichKen herrmannUniversity of california los angelesProstate cancer foundationDepartment of nuclear medicinePeter maccallum cancer centreUniversity of california san franciscoTargeted alpha therapiesTargeted alpha therapyCastration resistant prostate cancerTargeted alphaAdvancell advisory board memberNuclear medicine

AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer

SYDNEY (BUSINESS WIRE) AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with

United statesUniklinik essenAndrew adamovichKen herrmannUniversity of california los angelesProstate cancer foundationUniversity of california san franciscoDepartment of nuclear medicinePeter maccallum cancer centreTargeted alpha therapiesTargeted alpha therapyCastration resistant prostate cancerTargeted alphaAdvancell advisory boardNuclear medicineCancer lethality lead collaboration